Our Role

Elliogen is not an exploitant.
We operate as an independent, conflict-free advisor, bridging pharmaceutical companies with licensed exploitants in France. We help define the optimal market-entry model, identify the right partners, and avoid costly regulatory and commercial pitfalls.

---

Services

Marketing

We support pharmaceutical companies in launching or repositioning products in France and Europe.
Our work spans market intelligence, competitive positioning, branding, and patient-focused messaging — all grounded in robust market insight.

We leverage a strong network across manufacturers, distributors, wholesalers, French exploitants, and patient advocacy groups to support effective market access and visibility.

---

Business Development

We advise on partnership strategy and execution, from partner identification to early commercial discussions.
Our focus is on structuring sustainable collaborations aligned with both regulatory requirements and long-term commercial objectives.

---

Early Access Programs (EAP)

We provide end-to-end strategic support for Early Access Programs, ensuring regulatory alignment, operational readiness, and a clear pathway to future commercialisation — with patient access at the core.

 

Elliogen works with pharmaceutical companies entering or expanding in France and Europe, particularly where questions around exploitant models, partner selection, and regulatory responsibilities arise.

Not sure whether you need an exploitant — or which one?
Elliogen helps pharmaceutical companies assess the right market-entry model and connect with trusted Exploitant partners in France.

Book an Advisory Call